N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects

  title={N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects},
  author={Alessandro Minarini and Silvia Ferrari and Martina Galletti and Nina Giambalvo and Daniela Perrone and Giulia Rioli and Gian Maria Galeazzi},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={279 - 292}
ABSTRACT Introduction: N-acetylcysteine (NAC) is widely known for its role as a mucolytic and as an antidote to paracetamol overdose. There is increasing interest in the use of NAC in the treatment of several psychiatric disorders. The rationale for the administration of NAC in psychiatric conditions is based on its role as a precursor to the antioxidant glutathione, and its action as a modulating agent of glutamatergic, dopaminergic, neurotropic and inflammatory pathways. Areas covered: This… 
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
Current evidence supports N-acetylcysteine use as an adjunctive therapy clinically for psychiatric conditions, administered concomitantly with existing medications, with a recommended dosage between 2000 and 2400 mg/day.
Clinical Treatment of Addictive Disorders with N-Acetylcysteine
Overall evidence supports NAC affecting glutamate neurotransmission in addictive disorders, and given the favorable safety and tolerability profile of NAC, it may be a promising therapy for the treatment of addiction.
The Role of Antioxidants in the Management of Obsessive-Compulsive Disorder
Among antioxidants, NAC was one of the most studied drugs on OCD, and it showed a significant improvement in OCD symptoms, indicating that antioxidants could be promising as an adjuvant treatment for OCD.
N-acetyl-cysteine in schizophrenia—there is more than meets the eyes!
Light is shed on the promising therapeutic potential of NAC in schizophrenia spectrum disorders while examining the extant evidence.
Effect of N-acetylcysteine on clozapine-induced sialorrhea in schizophrenic patients: a case series
N-Acetylcysteine is a powerful antioxidant that acts directly as a scavenger of free radicals, in particular oxygen radicals, and modulates glutamatergic, neurotrophic and inflammatory pathways and there were no significant side effects of NAC as measured by the UKU scale.
N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy.
In WAG/Rij rats, NAC treatment significantly increased the number and duration of SWDs, aggravating absence epilepsy while ameliorating neuropsychiatric comorbidities, and was linked to an increase in brain mGlu2 receptor expression with this being likely responsible for the observed absence seizure-promoting effects.
Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive agents in the treatment of psychiatric disorders.
It is believed that ASA alone and its combination with gentisic acid should be studied in animal models of psychiatric disorders to reveal their potential in regard to the augmentation of currently available treatments.
The Potential of N-Acetylcysteine for Treatment of Trichotillomania, Excoriation Disorder, Onychophagia, and Onychotillomania: An Updated Literature Review
  • Debra K Lee, S. Lipner
  • Medicine, Psychology
    International journal of environmental research and public health
  • 2022
Although N-acetylcysteine has proven successful for treatment of BFRB disorders, data is derived from few clinical trials and case reports assessing small numbers of patients, and larger studies with longer durations are needed to fully establish the efficacy of NAC in these disorders.
Vitamin D and N-Acetyl cysteine supplementation in treatment resistant depressive disorder patients: a general review.
This paper reviews the therapeutic use of Vitamin D and NAC and among individuals with refractory MDD to the first- line pharmacological interventions, reviewing the clinical studies published in the last decade.
Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases
The purpose of this paper is to give an overview on the effects and applications of NAC in Parkinson's and Alzheimer's disorders and in neuropathic pain and stroke.


Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
N-acetylcysteine has shown promising results in populations with these disorders, including those in whom treatment efficacy has previously been limited, and the therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research.
N-acetylcysteine in the treatment of skin-picking disorder.
It is observed that discontinuation of NAC treatment led to worsening of symptoms, with remission of symptoms achieved again after rechallenge with NAC, suggesting a direct relation between NAC therapy and remission of skin-picking behavior.
The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Being negative at the week 12 end point, and with some positive secondary signals, the study provides only limited support for the role of NAC as a novel adjunctive therapy for MDD, although definitive confirmation remains necessary.
Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
NAC augmentation was effective in treating SRI-refractory OCD in this single case and further research is warranted to investigate the use of NAC and other glutamate modulating agents in the treatment of OCD.
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.
There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder.
Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine.
The clinical course of a 12-year-old female patient diagnosed with SPD that was treated with NAC is discussed, as this is an effective treatment for patients with obsessive-compulsive disorder (OCD).
N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study
NAC add-on therapy showed to be a safe and effective augmentative strategy for alleviating negative symptoms of schizophrenia.